Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On February 3, 2023, Barbara Duncan was elected to the Board of Directors of
Halozyme Therapeutics, Inc. (the "Company"). Ms. Duncan was elected to the class
of directors with terms ending at the Company's annual meeting of stockholders
in 2024. Ms. Duncan was initially assigned to serve on the Audit Committee. Ms.
Duncan will receive compensation for her services (currently consisting of cash
retainers for Board and committee service and restricted stock awards) under our
director compensation program applicable to all non-employee directors, as
revised from time to time. The current components of the non-employee director
compensation program were described in our proxy statement for the 2022 Annual
Meeting of Stockholders held on May 5, 2022.
There are no arrangements or understandings pursuant to which Ms. Duncan was
elected as a director and there are no related person transactions between the
Company and Ms. Duncan.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses